Diligence memo · auto-generated · as of July 3, 2026
EnGeneIC Ltd. (ABN: 59 091 336 499)
EnGeneIC Ltd. (ABN: 59 091 336 499) looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
EnGeneIC Ltd. (ABN: 59 091 336 499) operates in Biotechnology, based in LANE COVE, NEW SOUTH WALES.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
EnGeneIC Ltd. (ABN: 59 091 336 499) has raised $13M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.0M on 2014-08-25.
Most recent recorded round closed around 2014-12-12.
Valuation (modeled)modeled
Provath models EnGeneIC Ltd. (ABN: 59 091 336 499) at approximately $145M (range $4.4M–$786M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.91× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era. Within the normal band (91% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 11.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 61% of Biotechnology peers (4293 compared).
Modeled value ranks above 66% of those peers.
Closest niche peers: Dnanexus, Inc., Foresight Biotherapeutics, Inc., AuraSense Therapeutics, LLC, Zyomyx Inc, Champions Oncology, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.